iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details
Uncategorized
- Document Information
- Insider Trading Arrangements

Investments in Debt Securities

Investments in Debt Securities	6 Months Ended
Dec. 31, 2023
Investments in Debt and Equity Securities [Abstract]
Investments in Debt Securities	8. Investments in Debt Securities The Company did not hold any investments in debt securities at December 31, 2023 and June 30, 2023. Amortization of premiums paid on the debt securities amounted to $0 and $26,000 for the three months ended December 31, 2023 and 2022, respectively. Amortization of premiums paid on the debt securities amounted to $0 and $62,000 for the six months ended December 31, 2023 and 2022, respectively. No realized gains on available-for-sale debt securities were recognized for the three and six months ended December 31, 2023 and 2022.

Investments in Debt Securities

6 Months Ended

Dec. 31, 2023

Investments in Debt and Equity Securities [Abstract]

Investments in Debt Securities

8. Investments in Debt Securities

The Company did not hold any investments in debt securities at December 31, 2023 and June 30, 2023. Amortization of premiums paid on the debt securities amounted to $0 and $26,000 for the three months ended December 31, 2023 and 2022, respectively. Amortization of premiums paid on the debt securities amounted to $0 and $62,000 for the six months ended December 31, 2023 and 2022, respectively. No realized gains on available-for-sale debt securities were recognized for the three and six months ended December 31, 2023 and 2022.